CN Stock MarketDetailed Quotes

Chengdu Olymvax Biopharmaceuticals Inc (688319)

Watchlist
  • 29.12
  • +0.14+0.48%
Market Closed Apr 17 15:00 CST
11.81BMarket Cap529.45P/E (TTM)

Chengdu Olymvax Biopharmaceuticals Inc (688319) Revenue Breakdown Overview

By Product

Currency:CNY
2025/FY
Stock NameRevenueRatio
吸附破伤风疫苗613.66M87.15%
Group A C Meningococcal Polysaccharide binding Vaccine65.35M9.28%
Haemophilus influenzae type b combined vaccine18.76M2.66%
Other business4.03M0.57%
精制破伤风类毒素原液2.36M0.34%

By Industry

Currency:CNY
2025/FY
Stock NameRevenueRatio
Pharmaceutical manufacturing industry700.13M99.43%
Other business4.03M0.57%

By Country/Region

Currency:CNY
2025/FY
Stock NameRevenueRatio
East China294.16M41.77%
Southwest123.87M17.59%
Central China107.35M15.24%
South China78.01M11.08%
North China51.75M7.35%
Northwest28.29M4.02%
Northeast China16.7M2.37%
Other business4.03M0.57%
Total special adjustments--
View all

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Market Insights
Middle East conflict spreads to the stock market! How should investors respond?
On April 17, the Iranian foreign minister announced the opening of the Strait of Hormuz to merchant ships, and Trump immediately posted a me Show More